BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 37304674)

  • 1. Combining UBR5 and CD163
    Wang C; Hong T; Wang Y; Peng G; Yu Y; Zhang J; Zhuo D; Zheng J; Ma X; Cui X
    Cancer Immunol Immunother; 2021 Oct; 70(10):2925-2935. PubMed ID: 33710368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
    Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
    Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCDC25 suppresses clear cell renal cell carcinoma progression by LATS1/YAP-mediated regulation of the hippo pathway.
    Tan H; Liu J; Li Y; Mi Z; Liu B; Rong P
    Cancer Cell Int; 2024 Apr; 24(1):124. PubMed ID: 38570766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of ubiquitin-like modifier-activating enzyme 2 promotes apoptosis of clear cell renal cell carcinoma cells.
    Zhang G; Zou J; Shi J; Qian B; Qiu K; Liu Q; Xie T; He Z; Xu H; Liao Y; Wu Y; Li Y; Xiao G; Yuan Y; Xiao R; Wu G; Zou X
    Cell Death Dis; 2021 Nov; 12(11):1067. PubMed ID: 34753901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis.
    Wang J; Yin X; He W; Xue W; Zhang J; Huang Y
    Acta Pharm Sin B; 2021 Feb; 11(2):406-419. PubMed ID: 33643820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma.
    Schütte U; Bisht S; Heukamp LC; Kebschull M; Florin A; Haarmann J; Hoffmann P; Bendas G; Buettner R; Brossart P; Feldmann G
    Transl Oncol; 2014 Apr; 7(2):309-21. PubMed ID: 24913676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell transcriptome sequencing reveals aberrantly activated inter-tumor cell signaling pathways in the development of clear cell renal cell carcinoma.
    Zhang J; Liu F; Guo W; Bi X; Yuan S; Shayiti F; Pan T; Li K; Chen P
    J Transl Med; 2024 Jan; 22(1):37. PubMed ID: 38191424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clear cell renal cell carcinoma with syncytial giant cells: Not that rare.
    Sun W; Yue J; Fan L
    Pathol Res Pract; 2024 Jan; 253():155043. PubMed ID: 38183816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting a positive regulatory loop in the tumor-macrophage interaction impairs the progression of clear cell renal cell carcinoma.
    Wang C; Wang Y; Hong T; Ye J; Chu C; Zuo L; Zhang J; Cui X
    Cell Death Differ; 2021 Mar; 28(3):932-951. PubMed ID: 33009518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies.
    Schiavoni V; Campagna R; Pozzi V; Cecati M; Milanese G; Sartini D; Salvolini E; Galosi AB; Emanuelli M
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNF43 is a novel tumor-suppressor and prognostic indicator in clear cell renal cell carcinoma.
    Zhu D; Zhang L; Shi X; Gao S; Yue C; Zhang L; Bai YU; Wang Q; Okada A; Yasui T; Wang C; Cui X; Zuo LI
    Oncol Res; 2021; 29(3):159-174. PubMed ID: 37304674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNF43 is a Novel Tumor Suppressor and Prognostic Indicator in Clear Cell Renal Cell Carcinoma.
    Zhu D; Zhang L; Shi X; Gao S; Yue C; Zhang L; Bai Y; Wang Q; Okada A; Yasui T; Wang C; Cui X; Zuo L
    Oncol Res; 2021 Jul; ():. PubMed ID: 34215350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
    Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
    BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining expression of RNF43 and infiltration level of CD163
    Zhu D; Shi X; Tian Y; Li H; Tang B; Zhang Z; Zhang Z; Zuo L
    Cancer Med; 2023 Feb; 12(4):3962-3971. PubMed ID: 36097369
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.